Overview

Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis

Status:
Terminated
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The hypothesis being tested is that inhibition of the enzyme known as elastase in the airways of patients with cystic fibrosis will help decrease the number of bacteria. Alpha1 antitrypsin, an elastase inhibitor, will be given to patients with cystic fibrosis by aerosol therapy twice in 1 day and sputum will be collected to measure the density of bacteria
Phase:
Phase 2
Details
Lead Sponsor:
Université de Sherbrooke
Treatments:
Alpha 1-Antitrypsin
Protein C Inhibitor